-5%
Neumig tablet is used for the treatment of:
- Neuropathic pain
- Diabetic peripheral neuropathic pain (DPNP)
- Postherpetic neuralgia (PHN)
- Peripheral neuropathic pain (PNP)
Mirogabalin, the active ingredient in Neumig, belongs to the class of gamma-amino acids and their derivatives. It selectively binds to the α2δ subunits of voltage-gated calcium channels (VGCCs). This action reduces calcium influx into the neuron, inhibiting neurotransmitter release and decreasing hyper-excitability in the central nervous system (CNS).
After oral administration, Mirogabalin is quickly absorbed, with the maximum plasma concentration reached within 0.5 to 1.5 hours. It has low plasma protein binding (about 25%) and is widely distributed in the body, with a volume of distribution ranging from 64 to 88 L. The drug is mainly excreted unchanged (61-72%) via the kidneys, with a small fraction (13-20%) metabolized by the liver. The elimination half-life is 2 to 4.9 hours.
